Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma

European Journal of Cancer

Volumn 34, Issue 8, 1998, Pages 1198-1203

  Raedle, J ^a   Oremek, G ^a   Truschnowitsch, M ^a   Lorenz, M ^a   Roth, W K ^b   Caspary, W F ^a   Zeuzem, S ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Chemotherapeutisches F   (Germany)

Author keywords

fetoprotein; Chronic liver disease; Hepatoeellular carcinoma; p53 autoantibodies; Tumour screening

Indexed keywords

ALPHA FETOPROTEIN; AUTOANTIBODY; PROTEIN P53; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; AUTOIMMUNITY; CANCER SCREENING; CHRONIC LIVER DISEASE; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; AUTOANTIBODIES; CARCINOMA, HEPATOCELLULAR; CHRONIC DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LIVER DISEASES; LIVER NEOPLASMS; MALE; MIDDLE AGED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032127152     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00056-2     Document Type: Article

References (41)

1. 1. Harris CC, Hollstein M. Clinical implications of the p53 tumour-suppressor gene. N Engl J Med 1995, 329, 1318-1327.
2. 2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991, 253, 49-53.
3. 3. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991, 351, 453-456.
4. 4. Challen C, Lunec J, Warren W, Collier J, Bassendine MF. Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology 1992, 16, 1362-1366.
5. 5. Volkmann M, Hofmann WJ, Müller M, et al. P53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994, 9, 195-204.
6. 6. Harris CC. The 1995 Walter Hubert Lecture - Molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour-suppressor gene. Br J Cancer 1996, 73, 261-269.
7. 7. Angelopoulou K, Diamandis EP, Sutherland DJA, Kellen JA, Bunting PS. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994, 58, 480-487.
8. 8. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30, 403-408.
9. 9. Davidoff AM, Iglehart JD, Marks JR. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci USA 1992, 89, 3439-3442.
10. 10. Green JA, Mudenda B, Jenkins J, et al. Serum p53-antibodies: incidence in familial breast cancer. Eur J Cancer 1994, 30A, 580-584.
11. 11. Labrecque S, Naor N, Thomson D, Matlashewski G. Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993, 53, 3468-3471.
12. 12. Legros Y, Meyer A, Ory K, Soussi T. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. Oncogene 1994, 9, 3689-3694.
13. 13. Schlichtholz B, Trédaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br J Cancer 1994, 69, 809-816.
14. 14. Volkmann M, Müller M, Hofmann WJ, et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α-fetoprotein status. Hepatology 1993, 18, 559-565.
15. 15. Munoz N, Bosch FX. Epidemiology of hepatocellular carcinoma. In Okuda K, Ishak KG, eds. Neoplasms of the Liver. Tokyo, Springer, 1987, 3-19.
16. 16. Ikeda K, Saitoh S, Koida I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993, 18, 47-53.
17. 17. Liang TJ, Jeffers LJ, Reddy KR, et al. Viral pathogenesis of hepatocellular carcinoma in the United States. Hepatology 1993, 18, 1326-1333.
18. 18. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993, 328, 1797-1801.
19. 19. Cottone M, Turri M, Caltagirone M, et al. Early detection of hepatocellular carcinoma associated with cirrhosis by ultrasound and α-fetoprotein: a prospective study. Hepatogastroenterol 1988, 35, 101-103.
20. 20. Imberti D, Fornari F, Sbolli G, Buscarini E, Squassante L, Buscarini L. Hepatocellular carcinoma in liver cirrhosis. A prospective study. Scand J Gastroenterol 1993, 28, 540-544.
21. 21. Okuda K. Early recognition of hepatocellular carcinoma. Hepatology 1986, 6, 729-738.
22. 22. Solmi L, Primerano AMM, Gandolfi L. Ultrasound follow-up of patients at risk for hepatocellular carcinoma: results of a prospective study on 360 cases. Am J Gastroenterol 1996, 91, 1189-1194.
23. 23. Zoli M, Magalotti D, Bianchi G, Gueli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996, 78, 977-985.
24. 24. Colombo M, De Franchis R, Del Ninno E, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991, 325, 675-680.
25. 25. Ikeda K, Saitoh S, Koida I, et al. Imaging diagnosis of small hepatocellular carcinoma. Hepatology 1994, 20, 82-87.
26. 26. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S. Prospective study of α-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994, 19, 61-66.
27. 27. Sato Y, Nakata K, Kato Y, et al. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. N Engl J Med 1993, 328, 1802-1806.
28. 28. Raedle J, Roth WK, Oremek G, Caspary WF, Zeuzem S. α-Fetoprotein and p53 autoantibodies in patients with chronic hepatitis C. Dig Dis Sci 1995, 40, 2587-2594.
29. 29. Lubin R, Zalcman G, Bouchet L, et al. Serum p53 antibodies as early markers of lung cancer. Nature Med 1995, 1, 701-702.
30. 30. Trivers GE, Cawley HL, DeBenedetti VMG, et al. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995, 87, 1400-1407.
31. 31. Mudenda B, Green JA, Green B, et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. Br J Cancer 1994, 69, 1115-1119.
32. 32. Peyrat JP, Bonneterre J, Lubin R, Vanlemmens L, Fournier J, Soussi T. Prognostic significance of circulating p53 antibodies in patients undergoing surgery for locoregional breast cancer. Lancet 1995, 345, 621-622.
33. 33. Aguilar F, Harris CC, Sun T, Hollstein M, Cerutti P. Geographic variation of p53 mutational profile in nonmalignant human liver. Science 1994, 264, 1317-1319.
34. 34. Unsal H, Yakicier C, Marçais C, et al. Genetic heterogeneity of hepatocellular carcinoma. Proc Natl Acad Sci USA 1994, 91, 822-826.
35. 35. Galle PR, Müller M, Zentgraf H, Volkmann M. Detection of p53-antibodies by immunoblot and ELISA in various human malignancies - a new serological test? In Klapdor R, ed. Current Tumor Diagnosis: Applications, Clinical Relevance, Research, Trends. Cancer of the Lung-State and Trends in Diagnosis and Therapy. München, Zuckschwerdt, 1994, 562-564.
36. 36. Raedle J, Oremek G, Welker M, Roth WK, Caspary WF, Zeuzem S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996, 13, 241-246.
37. 37. Laurent-Puig P, Lubin R, Semhoun-Ducloux S, et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. Gut 1995, 36, 455-458.
38. 38. Arrowsmith CH, Morin P. New insights into p53 function from structural studies. Oncogene 1996, 12, 1379-1385.
39. 39. Livni N, Eid A, Ilan Y, et al. p53 expression in patients with cirrhosis with and without hepatocellular carcinoma. Cancer 1995, 75, 2420-2426.
40. 40. Marxsen J, Schmiegel W, Rôder C, et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. Br J Cancer 1994, 70, 1031-1034.
41. 41. Pateron D, Ganne N, Trinchet JC, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994, 20, 65-71.